Document is current
Any future updates will be listed below
-
Authors
Ye, Youqiong
Hu, Qingsong
Chen, Hu
Liang, Ke
Yuan, Yuan
Xiang, Yu
Ruan, Hang
Zhang, Zhao https://orcid.org/0000-0002-3757-8469
Song, Anren
Zhang, Huiwen
Liu, Lingxiang
Diao, Lixia
Lou, Yanyan
Zhou, Bingying
Wang, Li
Zhou, Shengtao
Gao, Jianjun
Jonasch, Eric
Lin, Steven H.
Xia, Yang
Lin, Chunru
Yang, Liuqing https://orcid.org/0000-0002-6518-474X
Mills, Gordon B.
Liang, Han https://orcid.org/0000-0001-7633-286X
Han, Leng https://orcid.org/0000-0002-7380-2640
- License Information
-
More Information
Article History
Received: 15 June 2018
Accepted: 14 February 2019
First Online: 18 March 2019
Competing interests
: G.B.M. has sponsored research support from AstraZeneca, Critical Outcomes Technologies, Karus Therapeutics, Illumina, Immunomet, NanoString, Tarveda Therapeutics and Immunomet. He is on the Scientific Advisory Boards of AstraZeneca, Critical Outcomes Technologies, Immunomet, Ionis Pharmaceuticals, Nuevolution, Symphogen and Tarveda Therapeutics. H.L. is a shareholder and scientific advisor of Precision Scientific and Eagle Nebula. J.G. serves as a consultant for ARMO Biosciences, AstraZeneca, Jounce Therapeutics, Nektar and Pfizer.
